General wellness product vs medical device: intended use and claims decide the boundary
A wellness label does not decide FDA status. A product may be outside the device definition, within a low-risk enforcement policy, regulated but exempt from a premarket submission, or covered by product-specific authorization. The first three are not clearance or approval.
A product is not outside FDA medical-device oversight merely because its seller calls it “wellness.” Intended use follows the claims and other objective-intent evidence. A product may fall outside the device definition, fit a low-risk enforcement policy, be regulated but exempt from a premarket submission, or have product-specific authorization. The first three descriptions do not mean FDA cleared or approved it.1234
The exact feature matters. One watch, app, scanner, or platform can contain an ordinary activity log, a low-risk wellness score, and a separately cleared medical feature. A status claim should name the feature, intended use, product version, decision, and date.
There are four different regulatory sentences
| Sentence | What it means | What it does not mean |
|---|---|---|
| This function is not a device | Its intended use does not place it within the federal device definition, including qualifying healthy-lifestyle software functions | FDA reviewed the function or found it clinically accurate |
| FDA does not intend to enforce specified requirements for this low-risk general-wellness product | The product fits the scope and risk conditions of FDA's current enforcement policy | FDA clearance, approval, authorization, certification, or endorsement |
| This device is regulated but premarket-exempt | The exact classification may allow marketing without a 510(k) or another premarket submission while other applicable device controls remain | FDA cleared or approved the product, or that every claim is permitted |
| This exact device or feature has an FDA marketing authorization | A named product and intended use followed a particular pathway such as clearance, De Novo authorization, or premarket approval | Every feature, claim, population, update, or later model is authorized |
“FDA compliant,” “built to FDA standards,” “FDA listed,” and “FDA registered” do not substitute for any of those precise sentences. The approval, clearance, and registration guide explains what record to request.
Intended use is broader than the disclaimer
Federal rules define intended use through the objective intent of the legally responsible persons, with relevant evidence including labeling, advertising, design, composition, and circumstances of distribution.4 A footer denying disease-diagnosis or treatment purposes cannot neutralize a dashboard, sales script, onboarding flow, clinician packet, or social campaign that makes those claims.
Capture the claim as a complete sentence:
- exact metric or output;
- named condition, health state, or lifestyle goal;
- action the user is told to take;
- intended population;
- required sensor, accessory, or professional interpretation;
- product and software version; and
- where the claim appeared.
“Tracks activity to support an active lifestyle” and “detects a heart condition” are not neighboring phrasings of the same intended use. Neither should be evaluated from the product category alone.
Healthy-lifestyle claims can sit outside the device definition
FDA’s 2026 general-wellness guidance describes one category involving claims that maintain or encourage a general state of health or healthy activity without referring to a disease or condition.12 Qualifying software functions may also be excluded from the device definition under federal law.
Examples of the claim shape—not verdicts on unnamed products—include encouraging sleep routines, physical activity, relaxation, healthy eating, or general fitness without diagnosing, treating, mitigating, preventing, or curing a disease. The complete product still needs review because sensors, outputs, alerts, and instructions can create a different intended use.
Being “not a device” is not a lower grade of clearance. It means the medical-device marketing pathway is not the applicable source of truth for that function. Evaluate the claim through evidence, consumer-protection law, privacy, cybersecurity, and the service context rather than asking for a clearance that does not apply.
Some disease-related wellness claims may fit a low-risk policy
FDA’s guidance also addresses certain low-risk products that promote, track, or encourage choices which, as part of a healthy lifestyle, may help reduce the risk or impact of specified chronic diseases or conditions when the association is well understood.12 The policy includes both the claim category and a low-risk analysis.
That is not a loophole for any disease claim. Ask:
- Is the healthy-lifestyle relationship generally accepted and accurately framed?
- Does the product merely encourage or track that choice, or does it claim to diagnose, select treatment, or replace clinical monitoring?
- Is the product invasive, implanted, or associated with another safety risk?
- Could a wrong output delay care or drive a medication change?
- Does the exact use stay inside the guidance examples and conditions?
“Enforcement discretion” describes FDA’s current enforcement approach for products within the policy. It is not a finding that the device is safe and effective for an authorized indication.
The same hardware can contain features with different status
A wearable may provide steps and sleep duration as wellness functions while offering an ECG, irregular-rhythm notification, glucose display, or another feature with a separate FDA record. The authorization may specify compatible hardware, software version, age range, prescription or over-the-counter status, and limitations.
Build a feature ledger:
| Feature | Exact claim | Regulatory statement | Record or policy basis | Version and date |
|---|---|---|---|---|
| Activity count | What the seller actually promises | Not-device analysis or wellness policy, if applicable | Current guidance plus claim capture | Hardware/app version |
| Risk score | Lifestyle support, disease-risk language, or diagnosis | Requires claim- and risk-specific analysis | Classification, exemption, or authorization record | Algorithm version |
| Medical alert | Screening, detection, monitoring, or diagnostic role | Product-specific device pathway | FDA database decision and labeling | Feature/version/date |
Do not let authorization for one row spread across the table. The OTC CGM guide shows how an authorized sensor can still be marketed inside a broader wellness program with separate claims and interpretations.
Enforcement letters are product-specific evidence
An FDA warning letter describes the agency’s concerns at a stated time. A close-out letter reflects the agency’s evaluation of corrective actions for that matter. Neither is a transferable approval, nor does closing a letter erase the need to read the product’s current claims and regulatory record. FDA’s 2026 WHOOP correspondence is a useful current example precisely because it is product- and conduct-specific.5
Ask what changed: claim wording, interface, instructions, distribution, feature availability, regulatory submission, or something else. Then inspect today’s version. A screenshot from before a correction cannot prove current status; a close-out link cannot authorize a new feature.
Apply the boundary before buying a program
- Separate the features. List each sensor, metric, score, alert, recommendation, and professional service instead of treating the platform as one regulated object.
- Capture intended use. Save the exact claim, audience, action, disclaimer, instructions, and sales context with a date and version.
- Classify the sentence. Distinguish not a device, low-risk enforcement discretion, regulated but premarket-exempt, and product-specific authorization.
- Verify any authorization. Match manufacturer, product, feature, model, indication, population, and labeling in the FDA record.
- Test evidence separately. Ask whether validation measures the promised output in the intended population and whether it improves the decision being sold.
- Preserve update accountability. Record how algorithm changes are disclosed, whether status changes by version, and who reviews unexpected results.
The decisive question is: “What exact intended use does this feature have today, and is the seller claiming it is outside the device definition, within a low-risk enforcement policy, regulated but premarket-exempt, or covered by a product-specific FDA authorization?”
Sources
- U.S. Food and Drug Administration. General Wellness: Policy for Low Risk Devices. FDA's January 2026 guidance on healthy-lifestyle claims, disease-related wellness claims, low-risk analysis, and enforcement discretion. Accessed .
- U.S. Food and Drug Administration. General Wellness: Policy for Low Risk Devices—Guidance for Industry and Food and Drug Administration Staff. Official guidance text and examples; guidance states FDA's current thinking and does not create binding rights or a product approval. Accessed .
- U.S. Food and Drug Administration. How to Determine if Your Product is a Medical Device. Device-definition, intended-use, product-classification, and regulatory-pathway starting points. Accessed .
- Code of Federal Regulations. 21 CFR § 801.4: Meaning of intended uses. Federal definition of intended uses and the objective-intent evidence relevant to a regulated product's purpose. Accessed .
- U.S. Food and Drug Administration. Close-Out Letter to WHOOP, Inc.. Current product-specific enforcement example showing that correspondence and corrective actions must be read in full rather than converted into category-wide status claims. Accessed .